Abstract
D The present study examined the association between granulocyte colony-stimulating factor (G-CSF) and prognostic markers cancer antigen (CA)27.29 and circulating tumor cells (CTCs) in 2646 early-stage breast cancer patients. Those with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy than those without any G-CSF application during chemotherapy, although no association with CTCs was found. Background: Little is known about the effect of granulocyte colony-stimulating factor (G-CSF) treatment during adjuvant chemotherapy on prognostic markers. The present study explored the association between G-CSF and changes in cancer antigen (CA) 27.29 and circulating tumor cell (CTC) levels during therapy. Patients and Methods: A total of 3754 node-positive or high-risk node-negative early-stage breast cancer patients were treated within the SUCCESS-A trial (simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial). CA27.29 and CTCs were determined before the start and within 6 weeks after the end of chemotherapy. Results: Overall, 1324 of the 2646 patients (50.0%) available for analysis had >= 1 G-CSF applications during chemotherapy. G-CSF application was significantly associated with CA27.29 status before and after chemotherapy (chi(2) = 30.6, df = 3;P < .001), because 238 patients (18.0%) with G-CSF treatment but only 146 (11.0%) without G-CSF treatment switched from a negative CA27.29 status before to a positive CA27.29 status after chemotherapy. In addition, patients with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy compared with patients without any G-CSF application during chemotherapy (Mann-Whitney U test;Z - -7.81, P < .001). No significant association was found between G-CSF application and CTC status before or after chemotherapy (chi(2) = 1.2, df = 3;P = .75). Conclusion: Cautious interpretation is needed regarding elevated levels of MUC-1 - derived tumor markers such as CA27.29 shortly after adjuvant chemotherapy when G-CSF has been given, because G-CSF treatment was associated with increased CA27.29 levels after chemotherapy.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 1526-8209 |
Sprache: | Englisch |
Dokumenten ID: | 65635 |
Datum der Veröffentlichung auf Open Access LMU: | 19. Jul. 2019, 12:18 |
Letzte Änderungen: | 04. Nov. 2020, 13:46 |